Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study of BIIB091 Formulations in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 59
- Registration Number
- NCT04564612
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 99
- Registration Number
- NCT04494256
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 46
- Registration Number
- NCT04488133
- Locations
- 🇪🇸
Hospital Sant Joan de Déu, Esplugues Del Llobregat, Barcelona, Spain
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Milan, Italy
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 440
- Registration Number
- NCT04476030
- Locations
- 🇺🇸
Sage Investigational Site, Bellevue, Washington, United States
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT04442503
- Locations
- 🇬🇧
Sage Investigational Site, Maidstone, United Kingdom
🇺🇸Sage Investigational SIte, North Canton, Ohio, United States
🇺🇸Sage Investigational site, Charleston, South Carolina, United States
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 543
- Registration Number
- NCT04442490
- Locations
- 🇺🇸
Sage Investigational Site, Charlottesville, Virginia, United States
Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT04419233
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 145
- Registration Number
- NCT04317794
- Locations
- 🇰🇷
Pusan Natioanl University Hospital, Busan, Korea, Republic of
🇰🇷Samsung Changwon Hospital, ChangWon, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 75
- Registration Number
- NCT04288856
- Locations
- 🇬🇧
Research Site, Sheffield, South Yorkshire, United Kingdom
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1696
- Registration Number
- NCT04241068
- Locations
- 🇨🇦
Montreal Neurological Institute Clinical Research Unit, Montréal, Quebec, Canada
🇫🇷CHU Lille - Hopital Roger Salengro, Lille Cedex, Nord, France
🇫🇷Hôpital Lariboisière, Paris cedex 10, Paris, France